Consensus RxSight, Inc.

Equities

RXST

US78349D1072

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
58.47 ^USD	-1.76%		-4.38%	+45.01%

May. 21	Rxsight Insider Bought Shares Worth $305,457, According to a Recent SEC Filing	MT
May. 15	Transcript : RxSight, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 through May-16-2024

Evolution of the average Target Price on RxSight, Inc.

Price target over the last 5 years

History of analyst recommendation changes

07234288e6d6fc1fd.cLQTg-z_n6gZT3DK-hSNLq4PKTzWxCAQaVuNar8jT00.OuIlwqa-qYVAIzGS1yW1bJdjWwWcp3dIGgK7BYlaeBJd2XCwlbrU5H58Aw~bc0bfe1d957dfe1ddac8d8736b572acc

Analyst Recommendations on RxSight, Inc.

Rxsight Insider Bought Shares Worth $305,457, According to a Recent SEC Filing	May. 21	MT
Wells Fargo Adjusts RxSight Price Target to $68 From $61, Maintains Overweight Rating	May. 07	MT
Oppenheimer Adjusts RxSight Price Target to $72 From $61, Maintains Outperform Rating	May. 07	MT
Needham Adjusts Price Target on RxSight to $75 From $64, Maintains Buy Rating	May. 07	MT
BTIG Adjusts Price Target on RxSight to $72 From $61, Maintains Buy Rating	May. 07	MT
Rxsight Insider Sold Shares Worth $526,913, According to a Recent SEC Filing	May. 02	MT
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing	Apr. 02	MT
Needham Raises Price Target on RxSight to $64 From $53, Maintains Buy Rating	Feb. 29	MT
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating	Feb. 29	MT
Stifel Adjusts Price Target on RxSight to $54 From $45, Maintains Buy Rating	Feb. 12	MT
Oppenheimer Raises RxSight Price Target to $54 From $50, Maintains Outperform Rating	Jan. 29	MT
Oppenheimer Raises RxSight Price Target to $50 From $46, Maintains Outperform Rating	Jan. 16	MT
Oppenheimer Ups Price Target on RxSight to $46 From $38, Maintains Outperform Rating	Jan. 08	MT
Needham Adjusts Price Target on RxSight to $41 From $35, Keeps Buy Rating	Jan. 08	MT
Wells Fargo Upgrades RxSight to Overweight From Equalweight, Price Target is $42	Dec. 13	MT
Stifel Starts RxSight With Buy Rating, $40 Price Target	Dec. 12	MT
Needham Adjusts RxSight Price Target to $30 From $36, Maintains Buy Rating	Nov. 10	MT
Oppenheimer Adjusts RxSight Price Target to $34 From $29, Maintains Outperform Rating	23-08-08	MT
Needham Adjusts Price Target on RxSight to $34 From $27, Maintains Buy Rating	23-07-12	MT
BTIG Adjusts Price Target on RxSight to $29 From $25, Maintains Buy Rating	23-06-05	MT
Wells Fargo Adjusts Price Target on RxSight to $27 From $17, Maintains Equalweight Rating	23-06-05	MT
Wells Fargo Adjusts RxSight Price Target to $17 From $15, Maintains Equal Weight Rating	23-05-10	MT
Oppenheimer Starts RxSight at Outperform With $23 Price Target, Sees Path to 'Meaningful' Gross Margin Expansion	23-04-13	MT
JPMorgan Adjusts Price Target on RxSight to $20 From $22, Maintains Overweight Rating	23-03-07	MT
Wells Fargo Downgrades RxSight to Equalweight From Overweight, Adjusts Price Target to $14 From $20	22-12-12	MT